TIM-3 is expressed on both immune and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs); its interaction with galectin-9 promotes LSCs self-renewal, making it a promising target in MDS/AML [59]. The gene discussed is LGALS9; the disease is myelodysplastic syndrome.